Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Pedmark® STS
Pedmark STS · 1 trial · 4 indications
| Name | Type | Description |
|---|---|---|
| Pedmark® STS | DRUG | Pedmark® STS (20 g/m2) will be given via intravenous infusion over 15-30 minutes, starting 6 hours after the completion of cisplatin infusion. Pedmark® STS will be given each day of cisplatin infusion. |
Pedmark STS is used for the prevention of cisplatin-induced ototoxicity in patients with solid tumor malignancies, including testicular, head and neck, and thoracic cancers. It is an investigational small molecule being studied in a Phase 2 clinical trial for this purpose.
Pedmark STS works by delivering sodium thiosulfate, which binds to cisplatin in the body and neutralizes its toxic effects on the inner ear, thereby protecting against hearing loss. This mechanism is being evaluated in the ongoing Phase 2 trial for solid tumor malignancies.
Pedmark STS is being developed by Fennec Pharmaceuticals Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol FENC. The company is conducting clinical research to evaluate the drug's safety and efficacy in preventing cisplatin-induced ototoxicity.
Pedmark STS is currently in Phase 2 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The ongoing Phase 2 trial is designed to assess its effectiveness in protecting against hearing loss in patients receiving cisplatin chemotherapy.
Pedmark STS is being studied in the Phase 2 clinical trial NCT07407582, titled 'Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)'. This trial is not yet recruiting and aims to enroll 25 patients with solid tumor malignancies, including testicular, head and neck, and thoracic cancers.
Yes, Pedmark STS is also known as Pedmark® STS. Both names refer to the same investigational drug being developed by Fennec Pharmaceuticals Inc. for the prevention of cisplatin-induced ototoxicity in patients with solid tumors.